Jammu, India

Kushalava Reddy Yempalla

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Anti-Mycobacterial Agents by Kushalava Reddy Yempalla

Introduction

Kushalava Reddy Yempalla is an innovative inventor based in Jammu, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-mycobacterial agents. His work focuses on addressing critical health challenges such as tuberculosis and its multidrug-resistant forms.

Latest Patents

Kushalava Reddy Yempalla holds a patent for "Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof." This invention relates to a new generation of triazole functionality containing 6-nitro-2,3-dihydroimidazooxazole agents. The patent outlines their method of preparation and their use as drugs for the treatment of tuberculosis, MDR-TB, and XDR-TB, either alone or in combination with other anti-tubercular agents. The general formula presented in the patent includes various functional groups that enhance the efficacy of these compounds.

Career Highlights

Kushalava Reddy Yempalla is associated with the Council of Scientific & Industrial Research, where he continues to advance research in medicinal chemistry. His work has been pivotal in developing new therapeutic agents that can combat resistant strains of tuberculosis.

Collaborations

Kushalava has collaborated with notable colleagues such as Gurunadham Munagala and Samsher Singh. These collaborations have fostered a productive research environment, leading to innovative solutions in the field of anti-mycobacterial research.

Conclusion

Kushalava Reddy Yempalla's contributions to the development of anti-mycobacterial agents highlight his commitment to addressing significant health issues. His innovative work continues to pave the way for new treatments in the fight against tuberculosis and its resistant forms.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…